177 related articles for article (PubMed ID: 22943172)
1. Investigation into the effect of varying l-leucine concentration on the product characteristics of spray-dried liposome powders.
Chen KH; Mueannoom W; Gaisford S; Kett VL
J Pharm Pharmacol; 2012 Oct; 64(10):1412-24. PubMed ID: 22943172
[TBL] [Abstract][Full Text] [Related]
2. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
Shetty N; Park H; Zemlyanov D; Mangal S; Bhujbal S; Zhou QT
Int J Pharm; 2018 Jun; 544(1):222-234. PubMed ID: 29678544
[TBL] [Abstract][Full Text] [Related]
3. Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes.
van den Hoven JM; Metselaar JM; Storm G; Beijnen JH; Nuijen B
Int J Pharm; 2012 Nov; 438(1-2):209-16. PubMed ID: 22960501
[TBL] [Abstract][Full Text] [Related]
4. Preparation and Characterization of Doripenem-Loaded Microparticles for Pulmonary Delivery.
Yildiz-Peköz A; Akbal O; Tekarslan SH; Sagirli AO; Mulazimoglu L; Morina D; Cevher E
J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):347-357. PubMed ID: 29877747
[No Abstract] [Full Text] [Related]
5. Investigation of the physical properties of spray-dried stabilised lysozyme particles.
Liao YH; Brown MB; Quader A; Martin GP
J Pharm Pharmacol; 2003 Sep; 55(9):1213-21. PubMed ID: 14604464
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
7. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
[TBL] [Abstract][Full Text] [Related]
8. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules.
Sou T; Kaminskas LM; Nguyen TH; Carlberg R; McIntosh MP; Morton DA
Eur J Pharm Biopharm; 2013 Feb; 83(2):234-43. PubMed ID: 23183447
[TBL] [Abstract][Full Text] [Related]
9. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
10. A Design of Experiment (DoE) approach to optimise spray drying process conditions for the production of trehalose/leucine formulations with application in pulmonary delivery.
Focaroli S; Mah PT; Hastedt JE; Gitlin I; Oscarson S; Fahy JV; Healy AM
Int J Pharm; 2019 May; 562():228-240. PubMed ID: 30849470
[TBL] [Abstract][Full Text] [Related]
11. Development of inhalable dry powder formulation of basic fibroblast growth factor.
Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
[TBL] [Abstract][Full Text] [Related]
12. The use of hydrophobic amino acids in protecting spray dried trehalose formulations against moisture-induced changes.
Mah PT; O'Connell P; Focaroli S; Lundy R; O'Mahony TF; Hastedt JE; Gitlin I; Oscarson S; Fahy JV; Healy AM
Eur J Pharm Biopharm; 2019 Nov; 144():139-153. PubMed ID: 31536784
[TBL] [Abstract][Full Text] [Related]
13. Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration.
Sou T; Morton DA; Williamson M; Meeusen EN; Kaminskas LM; McIntosh MP
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):361-71. PubMed ID: 25714115
[TBL] [Abstract][Full Text] [Related]
14. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
Pilcer G; Vanderbist F; Amighi K
Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
[TBL] [Abstract][Full Text] [Related]
16. Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery.
Ogáin ON; Li J; Tajber L; Corrigan OI; Healy AM
Int J Pharm; 2011 Feb; 405(1-2):23-35. PubMed ID: 21129458
[TBL] [Abstract][Full Text] [Related]
17. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims.
Thai A; Xiao J; Ammit AJ; Rohanizadeh R
Int J Pharm; 2010 Apr; 389(1-2):41-52. PubMed ID: 20080165
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery.
Feng AL; Boraey MA; Gwin MA; Finlay PR; Kuehl PJ; Vehring R
Int J Pharm; 2011 May; 409(1-2):156-63. PubMed ID: 21356284
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state.
Gad S; Tajber L; Corrigan OI; Healy AM
J Pharm Pharmacol; 2012 Sep; 64(9):1264-74. PubMed ID: 22881439
[TBL] [Abstract][Full Text] [Related]
20. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
